MOLECULAR PARTNERS TO PRESENT THE COMPLETED PHASE I DOSE ESCALATION INTERIM RESULTS OF MP0250 AT THE ANNUAL ESMO CONGRESS IN COPENHAGEN Mittwoch, 28. September 2016 - 12:44
 | ||||
| Press Release (PDF) | ||||
MOLECULAR PARTNERS TO PRESENT THE COMPLETED PHASE I DOSE ESCALATION INTERIM RESULTS OF MP0250 AT THE ANNUAL ESMO CONGRESS IN COPENHAGEN | ||||
| Zurich-Schlieren, September 28, 2016. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of therapies, known as DARPin® therapies, today announced that M.R. Middleton, MD at the Churchill Hospital, Oxford, UK will present interim data of the completed dose escalation, part of the MP0250 Phase I study, at the annual ESMO congress in Copenhagen on October 9th, 2016 at 3.00 PM CET.
The corresponding abstract is available on the ESMO webpage.
MP0250 is a multi- DARPin® product consisting of four domains targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) and also binds to human serum albumin (HSA) to increase the plasma half-life and potentially tissue penetration. | ||||
About Molecular Partners AG Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPin® therapies. DARPin® therapies are potent, specific, and versatile small proteins, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology has the potential to offer a multi-specific approach to treatment, which enables the DARPin® therapies to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPin® therapies have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. DARPin® is a registered trademark owned by Molecular Partners AG.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors.
For further details, please contact:
|